Discovery & Development Europe 2026

Causaly is the leading Agentic AI research platform for life sciences, designed to accelerate R&D through scientifically grounded, autonomous research workflows. Our agentic research capability orchestrates multi-step investigations by retrieving, analyzing, and synthesizing evidence across millions of scientific publications and data sources to deliver transparent, evidence-backed insights. Built on a proprietary knowledge graph of over 500 million evidence points, Causaly enables researchers to uncover disease mechanisms, identify novel targets, evaluate biomarkers, assess safety signals, and understand the competitive landscape. Trusted by leading biopharma organizations, Causaly supports decision-making across the full R&D lifecycle. From early discovery and translational research through clinical development and beyond, helping teams move from complex data to confident decisions faster.

BioDuro is a US company founded in 1996, and headquartered in Irvine, California. With more than 2,000+ scientists, we have 7 R&D and manufacturing campuses across the US and China. We offer fully integrated CRDMO services from discovery to commercial manufacturing across medicinal chemistry, biology, DMPK, drug substance and drug product, including multiple modalities small molecules, peptides, oligonucleotides and antibody drug conjugates. We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture. As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.

Sponsor biography coming soon

Cadence Molecular Sciences (OpenEye) offers state-of-the art solutions in computational molecular design through consulting services, robust and scalable software for the desktop, and Orion®, a cloud-native, software-as-a-service (SaaS) molecular modeling platform. Combining massive scale computation and storage with powerful tools for data sharing, visualization and analysis in a customizable development environment, Orion offers unprecedented capabilities for the discovery of small molecule drugs, biologics, agrochemicals, and flavors and fragrances.

Transforming drug discovery and development for good Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Certara acquired Chemaxon in 2024 to close gaps in the design-make-test-analyze cycle, bring promising leads into biosimulation, and speed up the launch of new medicines. Together, we help you innovate with confidence by turning your discovery process into a competitive advantage. We will present our cheminformatics software solutions for chemical drawing, molecule design, data analysis, and compound data management alongside our latest AI developments. Learn more at: https://www.certara.com/chemaxon/

High Q Technologies, based in Waterloo, Ontario, develops quantum-enabled EPR systems that help structural biologists, pharmaceutical researchers, and biotechnology teams resolve complex problems in protein dynamics and biomolecular structure. Our flagship instrument, FATHOM™, the world’s first quantum-enabled EPR spectrometer, provides high-resolution insights into protein conformations, distance distributions, and dynamics, generating detailed, publication-ready reports for each sample. Its innovative resonator design and automated workflows allow load-and-go operation for multiple samples, reducing acquisition times from days to hours, and capturing protein motions that are difficult or impossible with traditional EPR. FATHOM™ measures protein conformational dynamics at nanometer resolution and complements techniques such as Cryo-EM, AlphaFold predictions, and molecular dynamics simulations. The data gives researchers practical insights into protein behavior, useful for drug discovery and structural biology. In addition to instruments, High Q Technologies offers a Sample Measurement Service (SMS), giving researchers immediate access to high-resolution EPR data without in-house equipment. SMS provides flexible options, from single-sample analyses to fully managed measurement pipelines, including custom experimental design, pilot studies, and collaboration with our scientists for method development and data interpretation. For more information about FATHOM™ EPR or our Sample Measurement Service, contact us at www.highqtechnologies.com.

HitChem integrates advanced cheminformatics and cutting-edge language models to accelerate early-stage small molecule drug discovery. Our proprietary platform combines AI-driven molecule design with ultra-high-throughput screening to speed up hit identification and lead generation.

NYB.AI is an AI-native biotechnology company that maps indication biology, models drug–target interactions, and connects discovery data — end-to-end, in one platform, enabling pharma and biotech to improve upstream target confidence and hit quality.

Sponsor biography coming soon

Sponsor biography coming soon

Industry leading producer of neurons and glia paving the way for advancements in neuroscience. BrainXell was established in 2015 by Dr. Su-Chun Zhang, a pioneer in stem cell neuroscience, in collaboration with the University of Wisconsin–Madison’s Discovery to Product (D2P) program, to translate cutting-edge research into meaningful therapies. Today, the team works with both large and small biotech and pharmaceutical partners to develop products, services, and applications using its proprietary technology to guide human stem cells—including induced pluripotent stem cells (iPSCs)—into highly enriched, specialized neurons. BrainXell is working to bring hope to patients with neurological conditions. Our company is based on directed differentiation of human stem cells (including iPSCs) to highly enriched subclasses of neurons. BrainXell provides a range of high-purity, iPSC-derived human neurons for research and development with a focus on drug discovery. From motor neurons to cortical sub-types, we can provide specific models for both disease or normal drug screening. We are dedicated to delivering the highest quality products from both our off-the-shelf neurons as well as custom service projects.

Cell Signaling Technology is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. As a company of caring people driven by a devotion to facilitating good science, we are committed to doing the right thing for our customers, our communities, and our planet.

At Cellectricon, we create new avenues for drug discovery. With a broad platform for in vitro neurobiology research, we provide outstanding value for our Clients through highly customized services delivering scientific excellence, innovation, and quality of the highest of standards. Our services span the early discovery process where we help our Clients to obtain novel insights into disease biology and to identify targets and lead compounds with potential to produce first-in-class medicines. Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. Our services are focused on accelerating target and lead discovery programs in the areas of Peripheral Neuropathies, Neuroinflammation, Neurodegeneration and Neuroplasticity. Our Neurotoxicity Testing Services support the early safety assessment of drug candidates.

GeneFrontier offers a revolutionary cell-free protein expression platform, PUREfrex®. This highly customizable system enables precise control at the molecular level, making it ideal for producing a wide range of proteins including difficult-to-express proteins as well as for high-throughput screening of therapeutic biologics. By seamlessly integrating with AI/ML, PUREfrex® accelerates protein engineering and optimization, driving innovation in the biologics field.

HUB Organoids is the global leader in patient-derived organoid technology. Our patented technology enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system. We disrupt the status quo and deliver superior therapeutic solutions to the world by bridging the gap between the lab and the clinic.

Founded in 2000 as Merck & Co's Italian R&D site and independent since 2010, IRBM has pioneered drug discovery for oncology, neurological disorders, infectious diseases, and rare conditions. Our scientists work across small molecules, peptides, and antibody therapeutics, delivering three approved drugs and over 30 clinical candidates. From a fully integrated research facility, we combine deep scientific expertise with agile, end-to-end capabilities. Our internal pipeline features two oncology assets and one antiviral program, reflecting our relentless commitment to pushing the boundaries of therapeutic science.

Sponsor biography coming soon

Optibrium develops exceptional software and AI solutions that help scientists advance their drug discovery projects. Cutting-edge science, backed up by rigorous research, underpins their intuitive software for compound design, optimisation and data analysis. Optibrium’s comprehensive in silico platform improves the speed, efficiency, and productivity of the chemistry discovery process and supports a worldwide customer base, including leading biopharma companies. Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge MA.

SPERA PHARMA is a Japan‑based pharmaceutical CDMO providing CMC development and manufacturing services. The company leverages advanced structural and solid‑state analysis using 3D ED / MicroED, along with DIC‑based formulation technology for direct API capsule filling. Backed by know‑how from former leading‑pharma scientists and extensive global development experience, SPERA PHARMA supports highly potent APIs as well as high‑potency injectable products, including biologics. Working closely with regulatory and clinical partners, the company serves as a reliable gateway to Japan, enabling efficient development aligned with Japanese regulatory requirements.

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at http://www.wuxiapptec.com

Operating from state-of-the-art facilities in the UK, US and Europe, Almac Pharma Services is a fully regulatory approved CDMO partnering with global pharmaceutical and biotechnology industries. With over 55 years' experience, we provide a comprehensive range of tailored solutions and access to a wealth of technical experts to support the delivery of your complex projects. Almac’s integrated pharmaceutical development solutions are tailored to meet your needs. Our scientists can develop your clinical candidate into an optimum formulation and manufacture oral dose products for all stages of clinical trials. We specialise in the manufacture & primary packaging of oral dosage forms as well as customised secondary packaging for all drug products including ultra-low temperature drug products. Almac works in close partnership with our clients offering unique solutions designed to support the efficient and successful development, and commercialisation of new treatment options.

Sponsor biography coming soon

We help the life sciences industry to move from complex data to confident decisions, guided by clear, biology-driven insights. BioLizard partners with organizations of all sizes, from small pharmaceutical companies and startups to leading biotech and pharma companies, to extract meaningful insights from complex biomedical data. Bio|Verse®, our modular analytics platform, enables intuitive exploration, custom workflows, and scalable infrastructure built around your science.

CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We partner with global innovators to navigate today’s increasingly complex data landscape and uncover opportunities that drive meaningful progress. As specialists in scientific knowledge management, our team builds the world's largest, authoritative collection of human-curated scientific data and applies advanced technologies, proprietary capabilities, and deep domain expertise to solve our clients’ most difficult information challenges. Our unique combination of world-class content, technology, and data management expertise helps global innovators scale AI and drive innovation. CAS is a division of the American Chemical Society.

CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG provides state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG headquarters are in Montreal (Canada), with support offices in North America, Europe and Asia.

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by innovative biologists and chemists across academic, biotechnology, and pharmaceutical organizations. Its flagship platform, CDD Vault, enables researchers to securely manage and analyze both chemical and biological data through a user-friendly web interface. The platform supports entity registration, including small molecules, biologics, and complex modalities like ADCs, while offering robust inventory tracking, bioassay data management, SAR analysis, and experiment capture via its integrated Electronic Laboratory Notebook (ELN). CDD Vault also includes AI-powered tools for data mining and drug candidate prioritization, helping teams extract actionable insights more efficiently. Known for its intuitive design, strong performance, and secure collaboration workflows, CDD Vault facilitates seamless data sharing across internal teams and external partners. Founded in 2004, CDD today serves thousands of researchers worldwide, accelerating preclinical discovery and early-stage R&D efforts. Learn more at www.collaborativedrug.com

Sponsor biography coming soon

At Pelago Bioscience, we’re here to help you make faster, better-informed decisions in drug discovery. In 2010, our founders began to develop our proprietary CETSA® (Cellular Thermal Shift Assay) technology, publishing a seminal research paper in Science 2013. Since then, Pelago has become the leading CRO providing actionable, biologically relevant insights at the pre-clinical stage. Unlike traditional methods, CETSA allows us to assess drug-target interactions in physiologically relevant, unmodified cellular environments—so you can be confident that what you see in cells, you will also see in patients. Our services rest on four pillars: • Certainty in Biological Relevance: CETSA’s physiological approach helps minimize late-stage risks. • Fast & Early Confidence: We deliver actionable insights in just 4-10 weeks, eliminating unnecessary complexities so you can make decisions faster. • Insights & Progress: Our data supports compound prioritization and predicts future research steps, reducing project costs. • Extended Team Support: We work as your dedicated partner, designing fit-for-purpose studies that align with your goals. With Pelago, you gain more than just data;you gain a trusted partner in your discovery journey.

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Since 2009, X-Chem has led the way in DNA-encoded library (DEL) science and continues to evolve drug discovery. By combining DEL data with medicinal chemistry and computational sciences, we transform data into insights that accelerate and improve small molecule discovery. We partner with pharma and biotech innovators to deliver the clarity and confidence needed to move programs forward.

Ebenbuild GmbH is a Munich-based deep-tech healthcare company developing physics-based, patient-specific digital twins of the human lung. The company’s platform transforms standard CT data into validated digital lung models, making lung mechanics and function quantitatively accessible at the individual patient level. By enabling detailed analysis of airflow, tissue mechanics, and aerosol transport across the entire lung, Ebenbuild provides a robust technological foundation for applications in pharmaceutical research and development as well as for regulated clinical decision support in respiratory care. Based on this technology, Ebenbuild developed Twinhale, a simulation platform designed to support the development of inhaled drugs and drug–device combination products. Twinhale integrates CT-derived lung geometries, breathing patterns, and in vitro aerosol characteristics to predict regional lung deposition and the local dose at the site of action. By simulating structured virtual patient cohorts, the platform enables in silico trials that quantify variability in drug deposition across patient populations. These simulations support key development decisions, including device selection, formulation optimization, dose robustness assessments, and the generation of model-integrated evidence for bioequivalence, bridging, and regulatory discussions. Ebenbuild’s approach replaces assumptions with physics-based evidence, supporting more informed decisions in drug development and, over time, in the clinical management of patients with severe pulmonary diseases.

Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. Our connected data, deep expertise and intelligence platforms empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster. Clarivate is home to Cortellis, solutions for real world data, medtech, market access and commercialization and deep consulting expertise.